You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Populating MPS database with data from multi-organ, human-on-a-chip microphysiological systems

    SBC: HESPEROS, INC            Topic: 100

    Project Summary/Abstract: As stated in the Notice of Special Interest announcement, there is a need to populate the recently established MPS database with existing data generated by organ-on-a-chip systems. Having a centralized, public database with data from all available MPS systems will accelerate development and acceptance of the technology ultimately bringing better therapies to patients fast ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty

    SBC: Longeveron LLC            Topic: NIA

    Aging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Increasing size of Phase 2b clinical trial to 60 patients

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Project Summary/Abstract PTI-125 is a novel small molecule Alzheimer’s disease (AD) therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42’s tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42’s aberrant activati ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease

    SBC: SELEXYS PHARMACEUTICALS CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory disorder of the gastrointestinal tract that affects some 500,000 patients in the US. Selexys Pharmaceuticals is developing a fully human anti-PSGL- ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Functional integrated human-on-a-chip systems for Alzheimer's research

    SBC: HESPEROS, INC            Topic: NIA

    Project SummaryThe goal of this proposal, at the end of the Phase II effort, is to have a service available to academia and industry to screen drugs for Alzheimer’s to predict patient outcomes and determine how potential therapeutics are delivered to the CNS. There are currently few companies able to offer multi-organ evaluation with a recirculating medium utilizing functional readouts, and none ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical Development of OCF001 for Treatment of Yeast Infections

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. A computational platform to improve the prioritization of drugs and target genes for therapeutic intervention

    SBC: Genetic Networks, LLC            Topic: 100

    Project Summary This project proposes further development of a computational discovery platform shown to quantifiably identify and prioritize both targets and compounds for therapeutic intervention, which will accelerate the development of newer, more effective drugs with fewer side-effects. This platform is based on a novel fusion of two state of the art computational approaches (phenolog mapping ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government